torcetrapib

A compound called torcetrapib raised so-called good cholesterol, and Pfizer championed it—right up to the moment that a board monitoring the testing learned it was increasing patients' risk of dying.

Drug Makers Refill Parched Pipelines Jonathan D. Rockoff 2011

After 16 years and nearly $800 million in research, Pfizer halted development of a Lipitor successor called torcetrapib because of patient deaths in trials.

Pfizer's Future: A Niche Blockbuster Jonathan D. Rockoff 2011

Pfizer abruptly halted development of a similar drug called torcetrapib four years ago, in an $800 million debacle.

Cholesterol Drug Advances Ron Winslow 2010

"He was dealt a difficult hand when a promising cholesterol drug called torcetrapib failed and there was no successor to Lipitor," Funtleyder said, adding, "He might have done a better job."

Pfizer CEO Kindler, 55, Unexpectedly Replaced By LINDA A. JOHNSON 2010

The company had banked on another cholesterol-lowering drug, called torcetrapib, to provide a new source of growth.

Pfizer Plans to Abandon 2008

The company had banked on another cholesterol-lowering drug, called torcetrapib, to provide a new source of growth.

Pfizer Plans to Abandon 2008

Late last year, Pfizer lost its brightest hope on this front, a drug called torcetrapib that raised so-called good cholesterol and was personally championed by Mr. LaMattina, after that drug was linked to safety problems in premarket tests.

Pfizer Picks Insider as New Science Chief 2007

But much of the focus in Pfizer's pipeline is on a single drug, torcetrapib, which is designed to raise good cholesterol and clear plaque out of arteries.

Transforming Pfizer? Matthew Herper 2006

Neither drug caused high blood pressure, a problem that helped doom Pfizer's own CETP inhibitor, called torcetrapib.

Reuters: Press Release 2011

Neither drug caused high blood pressure, a problem that helped doom Pfizer's own CETP inhibitor, called torcetrapib.

unknown title 2011